Literature DB >> 32035193

Remodeling tumor immune microenvironment via targeted blockade of PI3K-γ and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy.

Man Li1, Mengmeng Li1, Yiliang Yang1, Yingke Liu2, Hanbing Xie3, Qianwen Yu1, Lifeng Tian1, Xian Tang1, Kebai Ren1, Jianping Li1, Zhirong Zhang1, Qin He4.   

Abstract

Immunotherapy has exhibited great potential in cancer treatment. However, for immunosuppressive tumors such as pancreatic cancer, immunotherapy is far from satisfactory. PI3K-γ and colony stimulating factor-1/colony stimulating factor-1 receptor (CSF-1/CSF-1R) pathways are involved in the infiltration and polarization of immunosuppressive cells including M2 tumor associated macrophages (M2 TAMs), causing a suppressive tumor immune microenvironment (TIME) in pancreatic cancer. Herein, a M2 TAM targeting nanomicelle was developed to co-deliver PI3K-γ inhibitor NVP-BEZ 235 and CSF-1R-siRNA for specific TAMs reprogramming and antitumor immune responses activation. M2 TAM targeting peptide M2pep was modified on a mixed micelle, which was potent to co-encapsulate BEZ 235 and CSF-1R siRNA. The formulated nanomicelle increased M2 TAM targeting efficiency both in vitro and in vivo. Compared with single pathway blockade, dual blockade of PI3k-γ and CSF-1R demonstrated enhanced TAM remodeling effects by reducing M2 TAM level and elevating M1 TAM level, and also suppressed tumor infiltration of myeloid-derived suppressor cells (MDSCs). Consequently, the M2 TAM targeting reprogramming system activated antitumor immune responses and achieved enhanced anti-pancreatic tumor effects via PI3K-γ blockade and downregulation of CSF-1R. The M2pep modified nanomicelle provides a promising method for co-delivery of siRNA and small molecule inhibitor to M2 TAM. Dual inhibition of both PI3K-γ and CSF-1R can remodel TIME and activate antitumor immune responses synergistically, providing an alternative approach for pancreatic cancer treatment.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CSF-1R; Immunotherapy; M2 TAM; PI3k-γ; Pancreatic cancer

Mesh:

Substances:

Year:  2020        PMID: 32035193     DOI: 10.1016/j.jconrel.2020.02.011

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  27 in total

Review 1.  Tailor-Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma.

Authors:  Xi Hu; Fan Xia; Jiyoung Lee; Fangyuan Li; Xiaoyang Lu; Xiaozhen Zhuo; Guangjun Nie; Daishun Ling
Journal:  Adv Sci (Weinh)       Date:  2021-02-12       Impact factor: 16.806

Review 2.  Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance.

Authors:  Thatcher Heumann; Nilofer Azad
Journal:  Cancer Metastasis Rev       Date:  2021-09-30       Impact factor: 9.264

Review 3.  Phosphoinositide 3-kinase/Akt and its related signaling pathways in the regulation of tumor-associated macrophages polarization.

Authors:  Depeng Yang; Lijun Yang; Jialing Cai; Huaxin Li; Zheng Xing; Ying Hou
Journal:  Mol Cell Biochem       Date:  2022-05-19       Impact factor: 3.842

4.  PI3Kγ inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response.

Authors:  Jie Li; Megan M Kaneda; Jun Ma; Ming Li; Ryan M Shepard; Kunal Patel; Tomoyuki Koga; Aaron Sarver; Frank Furnari; Beibei Xu; Sanjay Dhawan; Jianfang Ning; Hua Zhu; Anhua Wu; Gan You; Tao Jiang; Andrew S Venteicher; Jeremy N Rich; Christopher K Glass; Judith A Varner; Clark C Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-20       Impact factor: 11.205

5.  A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.

Authors:  Gerald S Falchook; Marc Peeters; Sylvie Rottey; Luc Y Dirix; Radka Obermannova; Jonathan E Cohen; Ruth Perets; Ronnie Shapira Frommer; Todd M Bauer; Judy S Wang; Richard D Carvajal; Joshua Sabari; Sonya Chapman; Wei Zhang; Boris Calderon; Daniel A Peterson
Journal:  Invest New Drugs       Date:  2021-04-14       Impact factor: 3.850

Review 6.  Peptides that immunoactivate the tumor microenvironment.

Authors:  Natsuki Furukawa; Aleksander S Popel
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-12-01       Impact factor: 10.680

7.  CD40 Agonists Alter the Pancreatic Cancer Microenvironment by Shifting the Macrophage Phenotype toward M1 and Suppress Human Pancreatic Cancer in Organotypic Slice Cultures.

Authors:  Chae Yoon Lim; Jae Hyuck Chang; Won Sun Lee; Jeana Kim; Il Young Park
Journal:  Gut Liver       Date:  2021-12-21       Impact factor: 4.321

8.  Magnetism-mediated targeting hyperthermia-immunotherapy in "cold" tumor with CSF1R inhibitor.

Authors:  Yuefei Fang; Yang He; Canhao Wu; Meng Zhang; Zeyun Gu; Jiaxin Zhang; Ergang Liu; Qin Xu; Akmal M Asrorov; Yongzhuo Huang
Journal:  Theranostics       Date:  2021-05-03       Impact factor: 11.556

Review 9.  Metabolic Cancer-Macrophage Crosstalk in the Tumor Microenvironment.

Authors:  Kyra E de Goede; Amber J M Driessen; Jan Van den Bossche
Journal:  Biology (Basel)       Date:  2020-11-07

Review 10.  Redefining Tumor-Associated Macrophage Subpopulations and Functions in the Tumor Microenvironment.

Authors:  Kaiyue Wu; Kangjia Lin; Xiaoyan Li; Xiangliang Yuan; Peiqing Xu; Peihua Ni; Dakang Xu
Journal:  Front Immunol       Date:  2020-08-04       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.